Answers are grounded in this paper and cite their sources.
Demonstrates the efficacy of Sabinineoside B in reducing liver disease symptoms in mice, suggesting its potential as a treatment option.
With the rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), the development of new drugs targeting this condition is particularly urgent. Sabinineoside B, a new compound of phenanthrene alkaloid glycoside isolated from the traditional Chinese herb Sabia parviflora. Through establishing a high-fat diet mouse model and integrating metabolomics, proteomics, and phosphoproteomics analyses, this study elucidated the efficacy and mechanism of Sabinineoside B in treating MASLD, while preliminarily evaluating its pharmacokinetics and safety. Molecular docking, molecular dynamics simulations, drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA), pull-down, dual-luciferase reporter gene assays and siRNA techniques were employed to validate the binding interaction between Sabinineoside B and key targets. We found that the Sabinineoside B protein significantly reduces lipid deposition and liver damage in mice on a high-fat diet. Integrated multi-omics analysis and Western blot experiments revealed that Sabinineoside B regulates lipid metabolism and exerts lipid-lowering effects by modulating the PPAR α signaling pathway. Knocking down PPAR α attenuates the regulatory effect of Sabinineoside B on the lipid-lowering pathway, indicating that the molecular mechanism of Sabinineoside B’s lipid-lowering activity may be achieved by targeting PPAR α. The novel phenanthrene alkaloid glycoside Sabinineoside B ameliorates metabolic dysfunction-associated fatty liver disease induced by a high-fat diet through the regulation of lipid metabolism via targeting PPAR α.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: